These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 33761699)

  • 21. Association of Intracranial Hemorrhage Risk With Non-Vitamin K Antagonist Oral Anticoagulant Use vs Aspirin Use: A Systematic Review and Meta-analysis.
    Huang WY; Singer DE; Wu YL; Chiang CE; Weng HH; Lee M; Ovbiagele B
    JAMA Neurol; 2018 Dec; 75(12):1511-1518. PubMed ID: 30105396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome.
    Varenhorst C; Jensevik K; Jernberg T; Sundström A; Hasvold P; Held C; Lagerqvist B; James S
    Eur Heart J; 2014 Apr; 35(15):969-78. PubMed ID: 24122961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial.
    Lopes RD; Vora AN; Liaw D; Granger CB; Darius H; Goodman SG; Mehran R; Windecker S; Alexander JH
    Am Heart J; 2018 Jun; 200():17-23. PubMed ID: 29898844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation.
    Lopes RD; Heizer G; Aronson R; Vora AN; Massaro T; Mehran R; Goodman SG; Windecker S; Darius H; Li J; Averkov O; Bahit MC; Berwanger O; Budaj A; Hijazi Z; Parkhomenko A; Sinnaeve P; Storey RF; Thiele H; Vinereanu D; Granger CB; Alexander JH;
    N Engl J Med; 2019 Apr; 380(16):1509-1524. PubMed ID: 30883055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is there a Role for Oral Triple Therapy in Patients with Acute Coronary Syndromes Without Atrial Fibrillation?
    Spinthakis N; Farag M; Akhtar Z; Gorog DA
    Curr Vasc Pharmacol; 2018; 16(5):427-436. PubMed ID: 29345587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis.
    Tavenier AH; Mehran R; Chiarito M; Cao D; Pivato CA; Nicolas J; Beerkens F; Nardin M; Sartori S; Baber U; Angiolillo DJ; Capodanno D; Valgimigli M; Hermanides RS; van 't Hof AWJ; Ten Berg JM; Chang K; Kini AS; Sharma SK; Dangas G
    Eur Heart J Cardiovasc Pharmacother; 2022 Aug; 8(5):492-502. PubMed ID: 34459481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a 'target trial'.
    Pufulete M; Harris J; Pouwels K; Reeves BC; Lasserson D; Loke YK; Mumford A; Mahadevan K; Johnson TW
    Open Heart; 2022 Aug; 9(2):. PubMed ID: 35961692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial.
    Kim BK; Hong SJ; Cho YH; Yun KH; Kim YH; Suh Y; Cho JY; Her AY; Cho S; Jeon DW; Yoo SY; Cho DK; Hong BK; Kwon H; Ahn CM; Shin DH; Nam CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y;
    JAMA; 2020 Jun; 323(23):2407-2416. PubMed ID: 32543684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.
    Watanabe H; Domei T; Morimoto T; Natsuaki M; Shiomi H; Toyota T; Ohya M; Suwa S; Takagi K; Nanasato M; Hata Y; Yagi M; Suematsu N; Yokomatsu T; Takamisawa I; Doi M; Noda T; Okayama H; Seino Y; Tada T; Sakamoto H; Hibi K; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Hanaoka KI; Morino Y; Kozuma K; Kadota K; Furukawa Y; Nakagawa Y; Kimura T;
    JAMA; 2019 Jun; 321(24):2414-2427. PubMed ID: 31237644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Three versus 12-month dual antiplatelet therapy duration in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
    Selvaraj V; Chatterjee S; Hirai T; Abbott JD; Bavishi C
    Catheter Cardiovasc Interv; 2022 Dec; 100(7):1151-1158. PubMed ID: 36326115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Performance of PRECISE-DAPT Score for Predicting Bleeding Complication During Dual Antiplatelet Therapy.
    Choi SY; Kim MH; Cho YR; Sung Park J; Min Lee K; Park TH; Yun SC
    Circ Cardiovasc Interv; 2018 Dec; 11(12):e006837. PubMed ID: 30545256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis.
    Oldgren J; Wallentin L; Alexander JH; James S; Jönelid B; Steg G; Sundström J
    Eur Heart J; 2013 Jun; 34(22):1670-80. PubMed ID: 23470494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strategies to Optimize Dual Antiplatelet Therapy After Coronary Artery Stenting in Acute Coronary Syndrome.
    Paravattil B; Elewa H
    J Cardiovasc Pharmacol Ther; 2017 Jul; 22(4):347-355. PubMed ID: 28587584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes.
    Alfredsson J; Neely B; Neely ML; Bhatt DL; Goodman SG; Tricoci P; Mahaffey KW; Cornel JH; White HD; Fox KA; Prabhakaran D; Winters KJ; Armstrong PW; Ohman EM; Roe MT;
    Heart; 2017 Aug; 103(15):1168-1176. PubMed ID: 28381584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anticoagulation strategies in patients with atrial fibrillation after PCI or with ACS : The end of triple therapy?
    Fluschnik N; Becher PM; Schnabel R; Blankenberg S; Westermann D
    Herz; 2018 Feb; 43(1):20-25. PubMed ID: 29188358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meta-Analysis of the Safety and Efficacy of the Oral Anticoagulant Agents (Apixaban, Rivaroxaban, Dabigatran) in Patients With Acute Coronary Syndrome.
    Khan SU; Arshad A; Riaz IB; Talluri S; Nasir F; Kaluski E
    Am J Cardiol; 2018 Feb; 121(3):301-307. PubMed ID: 29195825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized, double-blind trial to evaluate the safety of apixaban with antiplatelet therapy after acute coronary syndrome in Japanese patients (APPRAISE-J).
    Ogawa H; Goto S; Matsuzaki M; Hiro S; Shima D;
    Circ J; 2013; 77(9):2341-8. PubMed ID: 23748920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cangrelor or Clopidogrel in Patients with Type 2 Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials.
    Lu H; Guan W; Zhou Y; Tang Z; Bao H
    Diabetes Ther; 2019 Jun; 10(3):937-950. PubMed ID: 30905057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
    Gargiulo G; Ariotti S; Santucci A; Piccolo R; Baldo A; Franzone A; Magnani G; Marino M; Esposito G; Windecker S; Valgimigli M
    JACC Cardiovasc Interv; 2016 Sep; 9(17):1780-9. PubMed ID: 27544007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aspirin Alone Versus Dual Antiplatelet Therapy after Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis.
    Lin X; Wang S; Wang L; Guan Y; Huang J
    Cardiovasc Drugs Ther; 2022 Apr; 36(2):271-278. PubMed ID: 33570686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.